Akston Biosciences have recently received approval to conduct a Phase II/III clinical trial – the second stage of human testing, to check an intervention"s safety and efficacy – in India over the next year. It is hoped that the nature of its vaccine – which can be kept at room temperature for at least six months – could help reach regions with limited infrastructure needed to store and transport less stable vaccines. As such, while it may not become widely available until 2023, Zion is confident that it is still very relevant in the fight against Covid-19.